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Atherosclerosis is the underlying cause of ≈50% of all deaths in developed countries.1 An important rea-
son for this chronic inflammatory disorder to become life 
threatening is thrombus formation on ruptured atheroscle-
rotic plaques, resulting in myocardial infarction, peripheral 
artery disease, and stroke. Primary treatment of these dis-
orders is with antiplatelet (eg, aspirin and clopidogrel) and 
anticoagulant drugs (eg, warfarin, heparins, factor Xa, and 
thrombin inhibitors).2 These drugs are undeniably good in 
terms of effectiveness but have serious side effects of which 
bleeding is the most pronounced.3 To overcome these bleed-
ing problems, coagulation factor XI has been proposed as 
alternative target for anticoagulation4–7 because factor XI 
is associated with thrombosis, whereas it has a relatively 
minor role during normal hemostasis. This means that nor-
mal clot formation is still preserved in the absence of factor 
XI, while thrombosis is prevented. For example, inhibition 
of factor XI protects rodents and primates from experi-
mentally induced thrombosis in both arteries and veins.8–12 
Another argument for factor XI as antithrombotic target is 
the epidemiological evidence that patients with factor XI 
deficiency have a lower incidence of deep vein thrombosis 
and ischemic stroke.13,14
See accompanying editorial on page 1607
Until now, little is known about the role of factor XI inhibi-
tion in atherosclerosis and subsequent atherothrombosis. This 
is an important extension because atherosclerotic plaques con-
tain many components and cells with a thrombogenic potential 
beyond the coagulation cascade, such as oxidized low-density 
lipoproteins, lysophosphatidic acid, and macrophages.15,16 In 
addition, tissue factor (TF) and collagen are important deter-
minants of thrombus formation on ruptured plaques.15 The 
question is whether factor XI inhibition is capable to over-
come this prothrombotic environment. Because coagulation 
is not dependent on factor XI when high concentrations of 
TF are present,17,18 we questioned whether factor XI inhibition 
was still effective to prevent atherothrombosis.
© 2014 American Heart Association, Inc.
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Objective—Coagulation factor XI is proposed as therapeutic target for anticoagulation. However, it is still unclear whether 
the antithrombotic properties of factor XI inhibitors influence atherosclerotic disease and atherothrombosis. Our aim 
is to investigate whether factor XI antisense oligonucleotides could prevent thrombus formation on acutely ruptured 
atherosclerotic plaques.
Approach and Results—Atherosclerotic plaques in the carotid arteries of Apoe−/− mice were acutely ruptured using ultrasound. 
The subsequent thrombus formation was visualized and quantified by intravital microscopy and immunohistochemistry. 
Mice were pretreated with either factor XI antisense or nonsense oligonucleotides (50 mg/kg) to lower factor XI plasma 
levels. A tail bleeding assay was used to determine the safety. On plaque rupture, initial platelet adhesion and platelet 
plug formation were not impaired in animals treated with factor XI antisense oligonucleotides. However, the ensuing 
thrombus formation and fibrin deposition were significantly lower after 5 to 10 minutes (P<0.05) in factor XI antisense 
oligonucleotide–treated animals without inducing a bleeding tendency. Furthermore, thrombi from antisense-treated 
animals were less stable than thrombi from placebo-treated animals. Moreover, macrophage infiltration and collagen 
deposition were lower in the carotid arteries of factor XI antisense–treated animals. No neutrophils were present.
Conclusions—Factor XI antisense oligonucleotides safely prevent thrombus formation on acutely ruptured atherosclerotic 
plaques in mice. Furthermore, perturbed carotid arteries from factor XI antisense–treated animals show a less severe 
inflammatory response.  (Arterioscler Thromb Vasc Biol. 2014;34:1668-1673.)
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Furthermore, atherothrombotic disorders, such as myo-
cardial infarction and stroke, are diseases of the elderly and 
occur in patients with pronounced atherosclerotic vessels. In 
contrast, many animal experiments have been performed in 
young (4–8 weeks) mice with healthy nonatherosclerotic ves-
sels. In this study, we investigated the antithrombotic potential 
of factor XI antisense oligonucleotides in a model of plaque 
rupture, which is sensitive to both antiplatelet and antithrom-
botic therapy,15 in older (18–20 weeks) mice with pronounced 
atherosclerotic vessels. 
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results
Factor XI Affects Thrombus Formation 
on Ruptured Plaques
The role of factor XI in mouse models has only been estab-
lished in artificially damaged healthy vessels. Here, we stud-
ied the role of factor XI in thrombus formation after acute 
rupture of an atherosclerotic plaque in diseased vessels. 
Factor XI reduction was accomplished by injection of fac-
tor XI antisense oligonucleotides (50 mg/kg) in Apoe−/− mice 
fed with a high-fat diet to produce sufficient atherosclerosis.. 
Three injections with factor XI antisense oligonucleotides 
significantly reduced plasma factor XI activity levels to 20% 
(Figure 1A). Because the factor XI levels in the control group 
showed some variation, we normalized these levels for pro-
thrombin. As depicted in Figure 1B, prothrombin levels were 
not significantly different between groups. Subsequently, we 
calculated the mean factor XI/prothrombin ratio for both con-
trols (0.36) and factor XI antisense (0.13)–treated animals. By 
dividing these ratios, we found that factor XI levels were 2.8× 
lower in the plasma of factor XI antisense–treated animals 
than in the control group, corresponding to a 64% reduction 
of factor XI plasma levels.
Initially, in vivo thrombus formation after plaque rupture 
occurred similarly in both control Apoe−/− mice and Apoe−/− 
mice pretreated with factor XI antisense oligonucleotides 
(Figure 2A and 2B; Movies I and II in the online-only Data 
Supplement). However, pretreatment with factor XI antisense 
oligonucleotides reduced thrombus propagation and fibrin 
deposition, an effect that became significant 5 minutes after 
plaque rupture and continued for 10 minutes (Figure 2A and 
2B). Furthermore, the platelet aggregates seemed to be less 
stable than the thrombi formed in animals treated with non-
sense oligonucleotides as depicted by the number of platelets 
shed from the initial thrombus (Figure 2C). This indicates that 
inhibition of factor XI results in less stable clots, which should 
be a local event because systemic D-dimer levels were not 
different between groups (data not shown). Treatment with 
factor XI antisense oligonucleotides is safe in mice because 
the bleeding time was unaffected by the oligonucleotides 
(Figure 2D).
Reduced Thrombus Formation Is Partly Because 
of a Less Severe Inflammatory Response
To study the thrombi and plaques after the rupturing procedure 
in more detail, we poststained the carotid arteries and sub-
jected these to immunohistological analysis. Thrombus pheno-
type characteristics were determined by staining the sections 
for fibrin, macrophage differentiation antigen-3 (macrophage 
infiltration), lymfocyte antigen-6G (neutrophil recruitment), 
and with Sirius red (collagen) and hematoxylin and eosin. In 
the arteries of control Apoe−/− mice, thrombi contained many 
erythrocytes as a major component of a thrombus (Figure 3A). 
Factor XI antisense oligonucleotides significantly reduced 
thrombus size (14.1±4.0×103 μm2 total thrombus size) when 
compared with placebo-treated animals (68.4±23.9×103 μm2; 
n=4 per group; P<0.05) as shown in Figure 3B. Furthermore, 
using an antibody against fibrinogen, we observed fibrin fibers 
in the same thrombus within the carotid artery (Figure 3C, in 
brown; 29.9±10.2% of thrombus area; Figure 3D). In con-
trast, hardly any thrombi were observed in the carotid arteries 
of animals treated with factor XI antisense oligonucleotides 
as shown in Figure 3A and 3C (6.4±2.6% of thrombus area; 
Figure 3D; n=4 per group; P<0.05). Finally, to confirm that 
the thrombi are formed on a ruptured atherosclerotic plaque, 
we visualized the fibrous cap of the plaque using a Sirius red 
staining (Figure 3E). The fibrous cap with subsequent throm-
bus formation was only visible in control animals and not in 
the factor XI antisense–treated animals.
The (innate) immune system contributes to the initiation 
and amplification of venous thrombosis in mice.19 Especially, 
monocytes and neutrophils seem to be responsible for 
Nonstandard Abbreviation and Acronym
TF tissue factor
Figure 1. A and B, Effect of factor XI (FXI) anti-
sense on FXI activity and prothrombin levels in 
mouse plasma. Male Apoe−/− mice were fed a 
high-fat diet for 18 to 20 weeks, after which they 
were treated subcutaneously every 3 to 4 days 
with FXI antisense oligonucleotides for 10 days 
(dose 50 mg/kg). Each symbol represents 1 
animal, and the horizontal line indicates median, 
***P<0.0001, n=9 for the control group and n=13 
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thrombus formation. Therefore, we stained the carotid arteries 
for the presence of macrophages and neutrophils to investigate 
whether these cells are also involved during thrombus forma-
tion on ruptured atherosclerotic plaques. As shown in Figure 3F 
and 3G, there was a higher degree of macrophage infiltration 
in thrombi from placebo-treated animals than in factor XI anti-
sense–treated animals (18.5±1.1% versus 11.4±2.6 of throm-
bus area; n=4 per group; P=0.05). However, we did not observe 
any neutrophil infiltration in the thrombi from both control ani-
mals and factor XI antisense–treated animals (Figure 3H).
Discussion
The results of our study demonstrate that initial clot forma-
tion on atherosclerotic plaques is not impaired in mice treated 
with factor XI antisense drugs. Platelet adhesion and aggrega-
tion were not significantly different between treatment groups, 
which imply that primary hemostasis is not influenced by fac-
tor XI inhibition. However, because clots were significantly 
smaller after 5 to 10 minutes in the factor XI antisense group 
when compared with controls, this shows that secondary 






5 min 10 min
Control
5 min 10 min
1 min 3 min
Factor XI antisense
Figure 2. Effect of factor XI (FXI) antisense on thrombus formation on acutely ruptured atherosclerotic plaques. The carotid artery of 
Apoe−/− mice fed on a Western-type diet for 18 to 20 weeks was dissected free from surrounding tissue. Visible plaques were ruptured 
using an ultrasound wave. Subsequent thrombus formation was registered using intravital microscopy for a maximum of 30 minutes. Mice 
were treated with either FXI antisense (50 mg/kg; 3 injections) or nonsense oligonucleotides (control; 50 mg/kg; 3 injections). Depicted are 
representative fluorescent images after 1, 3, 5, and 10 minutes (A) and a quantification of thrombus formation and fibrin deposition using 
the integrated fluorescence intensity as described in the Materials and Methods in the online-only Data Supplement (B). Each bar graph 
represents the median value of 9 animals, error bars indicate interquartile ranges (IQR), *P<0.05. The number of fluorescent platelets shed 
were counted (independently by 2 investigators) for the first 3 minutes after plaque rupture and for 1 minute after t=5 and t=10 (C). Data 
are medians with IQR, *P<0.05. Atherosclerotic mice were given 3 doses of either factor XI antisense (50 mg/kg) or nonsense oligonucle-
otides (50 mg/kg). Tail bleeding was evaluated as described in the Materials and Methods in the online-only Data Supplement (D). Each 
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Figure 3. The role of factor XI in coagulation and inflammation. A, Images of the carotid artery stained with hematoxylin and eosin, used 
to visualize the extent of atherosclerotic plaque burden and erythrocyte infiltration. The arrow indicates a ruptured plaque. B, There was 
a significant difference in thrombus size between factor XI (FXI) antisense and placebo-treated animals. C, Sections were stained with an 
antifibrin(ogen) antibody to study thrombus formation. The arrow indicates the formed thrombus, with the fibrin threads in brown. D, Fibrin 
deposition was significantly lower in thrombi from factor XI antisense-treated animals when compared with placebo. E, The fibrous cap 
was visualized with a collagen staining (Sirius red) both in bright-field (top) and polarized light (bottom), the arrow indicates positive stain-
ing. F, Macrophage infiltration at the ruptured site was analyzed using macrophage differentiation antigen-3 staining. The arrow indicates 
positive staining; macrophages are in brown. G, Macrophage infiltration was not significantly different between the 2 treatment groups. H, 
Finally, the sections were stained for neutrophils using a lymfocyte antigen-6G antibody; however, no positive staining was observed. Error 
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This is the first study that focused on factor XI inhibition 
in diseased atherosclerotic vessels of older animals. Because 
atherosclerotic plaques contain a variety of prothrombotic 
substances, including TF, it is important to study the process 
of clot formation in ruptured plaques. We know from in vitro 
and in vivo studies that thrombus formation is probably less 
dependent on factor XI when there is a high concentration of 
TF.17,18 Furthermore, several other thrombogenic substances, 
such as oxidized low-density lipoproteins and macrophages, 
are exposed to the bloodstream after plaque rupture.15 Despite 
these prothrombotic conditions, factor XI inhibition resulted 
in smaller thrombi, which suggests that factor XI antisense 
may be used in patients having atherosclerosis-related disor-
ders, such as myocardial infarction and stroke. Because the 
plaque rupture model is known to be dependent on TF, these 
data indicate that, at least in mice, TF is a limiting factor in the 
in vivo coagulant activity, making the whole system dependent 
on factor XI. This observation on factor XI provides excellent 
possibilities for the secondary prevention of cardiovascular 
patients. Furthermore, previous experiments with this model 
have shown that this model relies on collagen exposure and 
that thrombus formation is inhibited by glycoprotein VI inhi-
bition and ADP receptor blockage, as well as inhibition of 
thrombin.15,20 Hence, we are able to conclude that thrombus 
formation on these ruptured plaques relies on both platelet 
activation (via glycoprotein VI and P2Y12) and coagulation.
We observed no differences in bleeding time between factor 
XI antisense and nonsense oligonucleotide–treated animals. 
This does not imply that (complete) factor XI inhibition in 
humans is safe. Patients with a severe factor XI deficiency 
may have a bleeding diathesis, whereas factor XI knockout 
mice do not have an increased bleeding tendency. This indi-
cates that there is a discrepancy between mice and humans 
about factor XI levels and bleeding.21
Because of the half-life of factor XI (≈48 hours), it takes 2 
to 3 days before an antithrombotic effect is observed in mice 
and men. In humans, because of multiple factors, it will prob-
ably take 1 to 3 weeks before antithrombotic protection can be 
achieved. These factors include the time needed for the fac-
tor XI antisense oligonucleotides to distribute effectively to 
hepatocytes and clearance of the existing factor XI in circu-
lation, which is dependent on its half-life. Nevertheless, this 
is a potential disadvantage of the drug. However, a treatment 
strategy incorporating heparins to bridge these first weeks 
before factor XI levels are reduced is probably a good solu-
tion. Most likely, the primary therapeutic use of factor XI anti-
sense oligonucleotides will be for prevention and treatment of 
thrombosis in conditions, such as atrial fibrillation and venous 
thromboembolism. Obviously, this has to be established in 
clinical trials.
Interestingly, clots were not only smaller but also more 
unstable in factor XI antisense–treated animals. Because we 
observed limited amounts of fibrin, this would suggest that 
the instability is because of insufficient thrombin generation 
and fibrin formation, rather than to the disintegration of pre-
formed rigid fibrin clots. Reduced thrombus stability in factor 
XI–deficient mice has been described before22; however, the 
explanation for this is not entirely clear. One possibility is that 
there is reduced activation of thrombin activatable fibrinolysis 
inhibitor, which protects the clot from degradation by plas-
min. This might cause enhanced fibrinolysis with less stable 
clots. An argument against this theory is that D-dimer levels 
were not significantly different between factor XI antisense– 
and nonsense–treated animals.
Because mice with an atherosclerotic phenotype do not 
develop spontaneous thrombosis, an artificial trigger is nec-
essary.23 Common methods, such as ferric chloride or Rose 
Bengal, produce large thrombi, which fully occlude the lumen 
of the vessel.24 However, thrombi formed on ruptured plaques 
in humans hardly ever cause full occlusion of the vessel.25,26 In 
addition, these methods do not expose the content of the plaque 
core with all its thrombogenic substances to the bloodstream. 
In our model, plaque rupture was induced with an ultrasound 
wave, which induced thrombus formation without affecting 
blood flow.15 The formed thrombi never fully occluded the 
vessel but did expose the plaque core to the bloodstream. 
Therefore, we think that this is an excellent model to study the 
dynamic process of thrombus formation on ruptured plaques. 
However, it is still a mouse model with an artificial trigger, so 
our model has to be translated to humans with some caution.
Inhibition of factor XI activation attenuates inflammation,27 
and indeed we found that macrophage infiltration was lower 
in thrombi from factor XI antisense–treated animals. This was 
only observed in thrombi formed on the ruptured plaques and 
not in the underlying plaque itself. Because factor XI activ-
ity might be involved in pathways that affect leukocyte func-
tion and trafficking, this observation could merely reflect a 
decrease in circulating leukocytes.28 At present, there is no 
known mechanistic link between factor XI activation and leu-
kocyte function although there is evidence that factor XIa has 
direct cellular signaling functions through various receptors.28 
Furthermore, factor XI is, together with factor XII and prekal-
likrein, a part of the contact system that constitutes a link 
between coagulation and inflammation,29 and inflammatory 
cells, such as activated neutrophils, are proposed to trigger 
coagulation.19 Therefore, inhibiting factor XI might suppress 
inflammatory pathways, which are responsible for pathologi-
cal thrombus formation on atherosclerotic plaques.
We conclude that inhibition of factor XI prevents thrombo-
sis on atherosclerotic plaques. The question remains whether 
factor XI inhibition influences the process of atherogenesis. 
Several clotting factors, including thrombin, contribute to 
atherosclerotic plaque formation.30 Therefore, it would be 
interesting to study the role of factor XI during this long-term 
process. Our current observations are that inhibition of fac-
tor XI prevents thrombosis on acutely ruptured atherosclerotic 
plaques without impairment of normal clot formation and 
indicates that targeting factor XI could be a safe alternative 
for the prevention of atherothrombotic disease.
Sources of Funding
This work was supported by a grant from the Netherlands Thrombosis 
Foundation (2009-4, to J.C.M. Meijers).
Disclosures
S Bhanot and B.P. Monia are employees of ISIS Pharmaceuticals. 




 http://ahajournals.org by on Septem
ber 15, 2021
Montfoort et al  Factor XI Regulates Atherothrombosis  1673
References
 1. Lusis AJ. Atherosclerosis. Nature. 2000;407:233–241.
 2. Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuunemann HJ. 
Executive summary: antithrombotic therapy and prevention of thrombosis, 
9th ed: American College of Chest Physicians Evidence-Based Clinical 
Practice Guidelines. Chest 2012:141:7S–47S.
 3. Levine MN, Raskob G, Beyth RJ, Kearon C, Schulman S. Hemorrhagic 
complications of anticoagulant treatment: the Seventh ACCP Conference 
on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(suppl 
3):287S–310S.
 4. Bouma BN, von dem Borne PA, Meijers JC. Factor XI and protection of 
the fibrin clot against lysis–a role for the intrinsic pathway of coagulation 
in fibrinolysis. Thromb Haemost. 1998;80:24–27.
 5. Gailani D, Renné T. The intrinsic pathway of coagulation: a target for 
treating thromboembolic disease? J Thromb Haemost. 2007;5:1106–1112.
 6. Gailani D, Renné T. Intrinsic pathway of coagulation and arterial thrombo-
sis. Arterioscler Thromb Vasc Biol. 2007;27:2507–2513.
 7. Löwenberg EC, Meijers JC, Monia BP, Levi M. Coagulation factor XI 
as a novel target for antithrombotic treatment. J Thromb Haemost. 
2010;8:2349–2357.
 8. Rosen ED, Gailani D, Castellino FJ. FXI is essential for thrombus forma-
tion following FeCl3-induced injury of the carotid artery in the mouse. 
Thromb Haemost. 2002;87:774–776.
 9. Wang X, Cheng Q, Xu L, Feuerstein GZ, Hsu MY, Smith PL, Seiffert DA, 
Schumacher WA, Ogletree ML, Gailani D. Effects of factor IX or factor 
XI deficiency on ferric chloride-induced carotid artery occlusion in mice. 
J Thromb Haemost. 2005;3:695–702.
 10. Wang X, Smith PL, Hsu MY, Gailani D, Schumacher WA, Ogletree ML, 
Seiffert DA. Effects of factor XI deficiency on ferric chloride-induced 
vena cava thrombosis in mice. J Thromb Haemost. 2006;4:1982–1988.
 11. Zhang H, Löwenberg EC, Crosby JR, MacLeod AR, Zhao C, Gao D, Black 
C, Revenko AS, Meijers JC, Stroes ES, Levi M, Monia BP. Inhibition 
of the intrinsic coagulation pathway factor XI by antisense oligonucle-
otides: a novel antithrombotic strategy with lowered bleeding risk. Blood. 
2010;116:4684–4692.
 12. Crosby JR, Marzec U, Revenko AS, Zhao C, Gao D, Matafonov A, 
Gailani D, MacLeod AR, Tucker EI, Gruber A, Hanson SR, Monia BP. 
Antithrombotic effect of antisense factor XI oligonucleotide treatment in 
primates. Arterioscler Thromb Vasc Biol. 2013;33:1670–1678.
 13. Salomon O, Steinberg DM, Zucker M, Varon D, Zivelin A, Seligsohn U. 
Patients with severe factor XI deficiency have a reduced incidence of deep-
vein thrombosis. Thromb Haemost. 2011;105:269–273.
 14. Salomon O, Steinberg DM, Koren-Morag N, Tanne D, Seligsohn U. 
Reduced incidence of ischemic stroke in patients with severe factor XI 
deficiency. Blood. 2008;111:4113–4117.
 15. Kuijpers MJ, Gilio K, Reitsma S, Nergiz-Unal R, Prinzen L, Heeneman 
S, Lutgens E, van Zandvoort MA, Nieswandt B, Egbrink MG, Heemskerk 
JW. Complementary roles of platelets and coagulation in thrombus 
formation on plaques acutely ruptured by targeted ultrasound treatment: 
a novel intravital model. J Thromb Haemost. 2009;7:152–161.
 16. Libby P. Mechanisms of acute coronary syndromes and their implications 
for therapy. N Engl J Med. 2013;368:2004–2013.
 17. Cheng Q, Tucker EI, Pine MS, Sisler I, Matafonov A, Sun MF, White-
Adams TC, Smith SA, Hanson SR, McCarty OJ, Renné T, Gruber A, 
Gailani D. A role for factor XIIa-mediated factor XI activation in throm-
bus formation in vivo. Blood. 2010;116:3981–3989.
 18. van Montfoort ML, Knaup VL, Marquart JA, Bakhtiari K, Castellino FJ, 
Hack CE, Meijers JC. Two novel inhibitory anti-human factor XI antibod-
ies prevent cessation of blood flow in a murine venous thrombosis model. 
Thromb Haemost. 2013;110:1065–1073.
 19. von Brühl ML, Stark K, Steinhart A, et al. Monocytes, neutrophils, and 
platelets cooperate to initiate and propagate venous thrombosis in mice in 
vivo. J Exp Med. 2012;209:819–835.
 20. Nergiz-Unal R, Cosemans JM, Feijge MA, van der Meijden PE, Storey 
RF, van Giezen JJ, oude Egbrink MG, Heemskerk JW, Kuijpers MJ. 
Stabilizing role of platelet P2Y(12) receptors in shear-dependent thrombus 
formation on ruptured plaques. PLoS One. 2010;5:e10130.
 21. van Montfoort ML, Meijers JC. Anticoagulation beyond direct thrombin 
and factor Xa inhibitors: indications for targeting the intrinsic pathway? 
Thromb Haemost. 2013;110:223–232.
 22. Renné T, Pozgajová M, Grüner S, Schuh K, Pauer HU, Burfeind P, Gailani 
D, Nieswandt B. Defective thrombus formation in mice lacking coagula-
tion factor XII. J Exp Med. 2005;202:271–281.
 23. Johnson JL, Jackson CL. Atherosclerotic plaque rupture in the apolipopro-
tein E knockout mouse. Atherosclerosis. 2001;154:399–406.
 24. Westrick RJ, Winn ME, Eitzman DT. Murine models of vascular thrombo-
sis (Eitzman series). Arterioscler Thromb Vasc Biol. 2007;27:2079–2093.
 25. Schwartz SM, Galis ZS, Rosenfeld ME, Falk E. Plaque rupture in humans 
and mice. Arterioscler Thromb Vasc Biol. 2007;27:705–713.
 26. Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM. Lessons 
from sudden coronary death: a comprehensive morphological classifica-
tion scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 
2000;20:1262–1275.
 27. Tucker EI, Verbout NG, Leung PY, Hurst S, McCarty OJ, Gailani D, 
Gruber A. Inhibition of factor XI activation attenuates inflammation and 
coagulopathy while improving the survival of mouse polymicrobial sepsis. 
Blood. 2012;119:4762–4768.
 28. Itakura A, Verbout NG, Phillips KG, Insall RH, Gailani D, Tucker EI, 
Gruber A, McCarty OJ. Activated factor XI inhibits chemotaxis of poly-
morphonuclear leukocytes. J Leukoc Biol. 2011;90:923–927.
 29. Renné T. The procoagulant and proinflammatory plasma contact system. 
Semin Immunopathol. 2012;34:31–41.
 30. Borissoff JI, Otten JJ, Heeneman S, et al. Genetic and pharmacological 
modifications of thrombin formation in apolipoprotein e-deficient mice 
determine atherosclerosis severity and atherothrombosis onset in a neutro-
phil-dependent manner. PLoS One. 2013;8:e55784.
This is the first study that establishes the importance of coagulation factor XI during atherothrombotic diseases. Current opinion assumes 
that atherothrombotic disorders, such as myocardial infarction and stroke, are mainly a platelet-driven event, accompanied by tissue factor–
initiated coagulation. In this study, we show that thrombus formation on acutely ruptured atherosclerotic plaques is dependent on factor XI, 
and that the thrombotic burden can be decreased by reducing factor XI levels using factor XI antisense oligonucleotides. Furthermore, inhibi-
tion of factor XI is not associated with an increased bleeding tendency, which indicates that targeting factor XI could be a safe alternative for 
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